Tetraphase’s sec­ond PhI­II for its lead an­tibi­ot­ic fails in a re­peat set­back for UTIs

Tetraphase $TTPH is 0 for 2 in Phase III stud­ies of its IV an­tibi­ot­ic er­ava­cy­cline for com­pli­cat­ed uri­nary tract in­fec­tions.

Re­searchers for the biotech say the an­tibi­ot­ic failed to achieve sta­tis­ti­cal non-in­fe­ri­or­i­ty to er­tapen­em on cUTIs, leav­ing it at a dead end. The biotech’s shares were once again shat­tered on the set­back, plung­ing 58%.

The Wa­ter­town, MA-based biotech was snubbed at the FDA more than a year ago when it tried to get a green light for the an­tibi­ot­ic in the wake of one suc­cess and one fail­ure in late-stage stud­ies. Tetraphase had one pos­i­tive re­sult for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions and the flop on com­pli­cat­ed UTIs when reg­u­la­tors sent them back in search of at least one more pos­i­tive study ahead of any ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER